Xoma | XOMA - Net Income


Xoma reported $-17.24M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Agenus USD -10.63M 74.49M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Ardelyx USD -407K 562K Dec/2025
aTyr Pharma USD 24.56M 50.3M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Curis USD 19.36M 31.16M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Incyte USD 299.28M 124.89M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -21.59M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024